Patents by Inventor Si-Yi Chen
Si-Yi Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240103817Abstract: A method, system, and computer program product for script generation and recommendation from behavior trees are provided. The method receives a set of input commands within a programming interface. The set of input commands is parsed into a set of command parts. The set of input commands is normalized based on the set of command parts to generate a set of normalized commands. A set of behavior trees are generated based on the set of normalized commands and the set of parts. The method generates a set of command scripts based on the set of behavior trees.Type: ApplicationFiled: September 23, 2022Publication date: March 28, 2024Inventors: Jing Zhao, Xiao Yun Wang, Si Yu Chen, Jiang Yi Liu, Jiangang Deng
-
Patent number: 8324369Abstract: The present invention provides adjuvants, vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The compositions and methods are useful for generating immune responses against antigens, including microbial pathogens and tumor-associated antigens, by way of inhibiting a negative immune regulator in a cell and providing a proinflammatory stimulus. In particular, nucleotides encoding inhibitors of negative immune regulators, antigens, and co-stimulatory molecules are contacted with immune cells in order to elicit a therapeutic or prophylactic response.Type: GrantFiled: November 26, 2008Date of Patent: December 4, 2012Assignee: Baylor College of MedicineInventor: Si-Yi Chen
-
Publication number: 20110281292Abstract: This invention relates to an expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked. More particularly, it relates to the method of eliciting an immune response directed against an antigen in a mammal comprising the steps of introducing the expression vector into a cell, expressing the vector to produce an antigen under conditions wherein the antigen is secreted from the cell, endocytosing the secreted antigen into the cell, processing the antigen, and presenting fragments to a receptor to elicit a T-cell response. In addition, this invention relates to a vaccine and a method of use. The invention also relates to the method of identifying MHC-II restricted epitopes.Type: ApplicationFiled: July 2, 2010Publication date: November 17, 2011Inventors: Si-Yi Chen, Zhaoyang You
-
Patent number: 7868159Abstract: The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell. The present invention provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.Type: GrantFiled: January 19, 2006Date of Patent: January 11, 2011Assignee: Baylor College of MedicineInventors: Si-Yi Chen, Kevin C. Evel-Kabler, Xiaotong Song, Xue F. Huang, Andrew Sharabi
-
Patent number: 7868158Abstract: The present invention relates to regulation of antigen presentation by cytokine signaling regulators in antigen presenting cells, such as dendritic cells. The invention provides methods of modulating antigen presentation through modulation of cytokine signaling regulators, such as SOCS (SOCS1-7, CIS), SHP (SHP-1 and SHP-2) or PIAS (PIAS1, PIAS3, PIASx and PIASy). The present invention provides vaccines and therapies in which antigen presentation is enhanced through modulation of cytokine signaling regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.Type: GrantFiled: June 23, 2005Date of Patent: January 11, 2011Assignee: Baylor College of MedicineInventors: Si-Yi Chen, Lei Shen, Kevin C. Evel-Kabler, Xue F. Huang
-
Publication number: 20100255023Abstract: The present invention provides adjuvants, vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The compositions and methods are useful for generating immune responses against antigens, including microbial pathogens and tumor-associated antigens, by way of inhibiting a negative immune regulator in a cell and providing a proinflammatory stimulus. In particular, nucleotides encoding inhibitors of negative immune regulators, antigens, and co-stimulatory molecules are contacted with immune cells in order to elicit a therapeutic or prophylactic response.Type: ApplicationFiled: November 26, 2008Publication date: October 7, 2010Inventor: Si-Yi Chen
-
Patent number: 7749752Abstract: This invention relates to an expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked. More particularly, it relates to the method of eliciting an immune response directed against an antigen in a mammal comprising the steps of introducing the expression vector into a cell, expressing the vector to produce an antigen under conditions wherein the antigen is secreted from the cell, endocytosing the secreted antigen into the cell, processing the antigen, and presenting fragments to a receptor to elicit a T-cell response. In addition, this invention relates to a vaccine and a method of use. The invention also relates to the method of identifying MHC-II restricted epitopes.Type: GrantFiled: August 31, 2007Date of Patent: July 6, 2010Assignee: Wake Forest University Health SciencesInventors: Si-Yi Chen, Zhaoyang You
-
Publication number: 20080131871Abstract: This invention relates to an expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked. More particularly, it relates to the method of eliciting an immune response directed against an antigen in a mammal comprising the steps of introducing the expression vector into a cell, expressing the vector to produce an antigen under conditions wherein the antigen is secreted from the cell, endocytosing the secreted antigen into the cell, processing the antigen, and presenting fragments to a receptor to elicit a T-cell response. In addition, this invention relates to a vaccine and a method of use. The invention also relates to the method of identifying MHC-II restricted epitopes.Type: ApplicationFiled: August 31, 2007Publication date: June 5, 2008Applicant: Wake Forest University Health SciencesInventors: Si-Yi Chen, Zhaoyang You
-
Patent number: 7273752Abstract: This invention relates to an expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked. More particularly, it relates to the method of eliciting an immune response directed against an antigen in a mammal comprising the steps of introducing the expression vector into a cell, expressing the vector to produce an antigen under conditions wherein the antigen is secreted from the cell, endocytosing the secreted antigen into the cell, processing the antigen, and presenting fragments to a receptor to elicit a T-cell response. In addition, this invention relates to a vaccine and a method of use. The invention also relates to the method of identifying MHC-II restricted epitopes.Type: GrantFiled: October 8, 2003Date of Patent: September 25, 2007Assignee: Wake Forest University Health SciencesInventors: Si-Yi Chen, Zhaoyang You
-
Patent number: 7186697Abstract: A nucleic acid delivery system is described. The delivery system contains a fusion protein having a target moiety and a nucleic acid binding moiety, and a nucleic acid sequence bound to the nucleic acid binding moiety of the fusion protein. The target moiety can be an antibody or a ligand. The use of this nucleic acid delivery system to transienntly or stably express a desired nucleic acid sequence in a cell is disclosed. Also disclosed is the use of this delivery system to target a cell and deliver a desired product.Type: GrantFiled: March 24, 1997Date of Patent: March 6, 2007Assignee: Dana-Farber Cancer InstituteInventors: Wayne A. Marasco, Si-Yi Chen
-
Publication number: 20060292119Abstract: The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell. The present invention provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.Type: ApplicationFiled: January 19, 2006Publication date: December 28, 2006Inventors: Si-Yi Chen, Kevin Evel-Kabler, Xiaotong Song, Xue Huang, Andrew Sharabi
-
Publication number: 20060269519Abstract: The present invention relates to regulation of antigen presentation by cytokine signaling regulators in antigen presenting cells, such as dendritic cells. The invention provides methods of modulating antigen presentation through modulation of cytokine signaling regulators, such as SOCS (SOCS1-7, CIS), SHP (SHP-1 and SHP-2) or PIAS (PIAS1, PIAS3, PIASx and PIASy). The present invention provides vaccines and therapies in which antigen presentation is enhanced through modulation of cytokine signaling regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.Type: ApplicationFiled: June 23, 2005Publication date: November 30, 2006Inventors: Si-Yi Chen, Lei Shen, Kevin Evel-Kabler, Xue Huang
-
Publication number: 20040096426Abstract: This invention relates to an expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked. More particularly, it relates to the method of eliciting an immune response directed against an antigen in a mammal comprising the steps of introducing the expression vector into a cell, expressing the vector to produce an antigen under conditions wherein the antigen is secreted from the cell, endocytosing the secreted antigen into the cell, processing the antigen, and presenting fragments to a receptor to elicit a T-cell response. In addition, this invention relates to a vaccine and a method of use. The invention also relates to the method of identifying MHC-II restricted epitopes.Type: ApplicationFiled: October 8, 2003Publication date: May 20, 2004Applicant: Wake Forest UniversityInventors: Si-Yi Chen, Zhaoyang You
-
Patent number: 6716623Abstract: This invention relates to an expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked. More particularly, it relates to the method of eliciting an immune response directed against an antigen in a mammal comprising the steps of introducing the expression vector into a cell, expressing the vector to produce an antigen under conditions wherein the antigen is secreted from the cell, endocytosing the secreted antigen into the cell, processing the antigen, and presenting fragments to a receptor to elicit a T-cell response. In addition, this invention relates to a vaccine and a method of use. The invention also relates to the method of identifying MHC-II restricted epitopes.Type: GrantFiled: July 22, 2002Date of Patent: April 6, 2004Assignee: Wake Forest University School of MedicineInventors: Si-Yi Chen, Zhaoyang You
-
Publication number: 20040023902Abstract: A nucleic acid delivery system is described. The delivery system contains a fusion protein having a target moiety and a nucleic acid binding moiety, and a nucleic acid sequence bound to the nucleic acid binding moiety of the fusion protein. The target moiety can be an antibody or a ligand. The use of this nucleic acid delivery system to transienntly or stably express a desired nucleic acid sequence in a cell is disclosed. Also disclosed is the use of this delivery system to target a cell and deliver a desired product.Type: ApplicationFiled: March 24, 1997Publication date: February 5, 2004Inventors: WAYNE A. MARASCO, SI-YI CHEN
-
Publication number: 20030166140Abstract: This invention relates to an expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked. More particularly, it relates to the method of eliciting an immune response directed against an antigen in a mammal comprising the steps of introducing the expression vector into a cell, expressing the vector to produce an antigen under conditions wherein the antigen is secreted from the cell, endocytosing the secreted antigen into the cell, processing the antigen, and presenting fragments to a receptor to elicit a T-cell response. In addition, this invention relates to a vaccine and a method of use. The invention also relates to the method of identifying MHC-II restricted epitopes.Type: ApplicationFiled: July 22, 2002Publication date: September 4, 2003Applicant: Wake Forest UniversityInventors: Si-Yi Chen, Zhaoyang You
-
Publication number: 20030143228Abstract: The present invention relates to the identification of MHC-I and MHC-II hTRT restricted epitopes and the use of these identified epitopes to elicit an immune response against the epitope. More particularly, the identified epitopes are administered to a subject to treat hyperproliferative diseases.Type: ApplicationFiled: October 29, 2002Publication date: July 31, 2003Applicant: Baylor College of MedicineInventors: Si-Yi Chen, Roland Schroers
-
Patent number: 6500641Abstract: This invention relates to an expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked. More particularly, it relates to the method of eliciting an immune response directed against an antigen in a mammal comprising the steps of introducing the expression vector into a cell, expressing the vector to produce an antigen under conditions wherein the antigen is secreted from the cell, endocytosing the secreted antigen into the cell, processing the antigen, and presenting fragments to a receptor to elicit a T-cell response. In addition, this invention relates to a vaccine and a method of use. The invention also relates to the method of identifying MHC-II restricted epitopes.Type: GrantFiled: May 5, 2000Date of Patent: December 31, 2002Assignee: Wake Forest University School of MedicineInventors: Si-Yi Chen, Zhaoyang You